These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1909 related items for PubMed ID: 33988036

  • 1. Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.
    Dal Maso A, Lorenzi M, Ferro A, Pilotto S, Cecere F, Follador A, Polo V, Del Conte A, Sartori G, Giavarra M, Scattolin D, Indraccolo S, Frega S, De Maglio G, Menis J, Bonanno L, Calabrese F, Guarneri V, Conte P, Pasello G.
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [Abstract] [Full Text] [Related]

  • 2. Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.
    Xie L, Nagpal S, Wakelee HA, Li G, Soltys SG, Neal JW.
    Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
    [Abstract] [Full Text] [Related]

  • 3. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T, Kasai T, Okada M, Nakachi I, Soda S, Arai R, Takigami A, Sata M.
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [Abstract] [Full Text] [Related]

  • 4. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
    Miyashita Y, Ko R, Shimada N, Mitsuishi Y, Miura K, Matsumoto N, Asao T, Shukuya T, Shibayama R, Koyama R, Takahashi K.
    Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
    [Abstract] [Full Text] [Related]

  • 5. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
    Li C, Nie W, Guo J, Xiong A, Zhong H, Chu T, Zhong R, Xu J, Lu J, Zheng X, Zhang B, Shen Y, Pan F, Han B, Zhang X.
    Respir Res; 2021 May 11; 22(1):145. PubMed ID: 33975616
    [Abstract] [Full Text] [Related]

  • 6. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
    Hochmair MJ, Buder A, Schwab S, Burghuber OC, Prosch H, Hilbe W, Cseh A, Fritz R, Filipits M.
    Target Oncol; 2019 Feb 11; 14(1):75-83. PubMed ID: 30539501
    [Abstract] [Full Text] [Related]

  • 7. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.
    Chang GC, Shih JY, Yu CJ, Chao HS, Yang CT, Lin CC, Hung JY, Hsiao SY, Wang CC, Chian CF, Hsia TC, Chen YM.
    PLoS One; 2024 Feb 11; 19(5):e0303046. PubMed ID: 38753697
    [Abstract] [Full Text] [Related]

  • 8. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
    Nakashima K, Kimura M, Akamatsu H, Daga H, Imai H, Taira T, Ko R, Hisamatsu Y, Nishino K, Sugimoto T, Miyashita Y, Takahashi T, et al.
    Jpn J Clin Oncol; 2019 Jul 01; 49(7):671-675. PubMed ID: 30920616
    [Abstract] [Full Text] [Related]

  • 9. Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI.
    Chiang CL, Huang HC, Shen CI, Luo YH, Chen YM, Chiu CH.
    Target Oncol; 2020 Aug 01; 15(4):503-512. PubMed ID: 32696212
    [Abstract] [Full Text] [Related]

  • 10. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y, Hao X, Xing P, Hu X, Wang Y, Li T, Zhang J, Xu Z, Li J.
    J Cancer Res Clin Oncol; 2020 Sep 01; 146(9):2427-2433. PubMed ID: 32385709
    [Abstract] [Full Text] [Related]

  • 11. Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
    Kraskowski O, Stratmann JA, Wiesweg M, Eberhardt W, Metzenmacher M, Schmid KW, Herold T, Schildhaus HU, Darwiche K, Aigner C, Stuschke M, Laue K, Zaun G, Kasper S, Hense J, Sebastian M, Schuler M, Pogorzelski M.
    J Cancer Res Clin Oncol; 2023 Sep 01; 149(11):9243-9252. PubMed ID: 37198447
    [Abstract] [Full Text] [Related]

  • 12. Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial.
    Nakashima K, Ozawa Y, Daga H, Imai H, Tamiya M, Tokito T, Kawamura T, Akamatsu H, Tsuboguchi Y, Takahashi T, Yamamoto N, Mori K, Murakami H.
    Invest New Drugs; 2020 Dec 01; 38(6):1854-1861. PubMed ID: 32424780
    [Abstract] [Full Text] [Related]

  • 13. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
    Auliac JB, Pérol M, Planchard D, Monnet I, Wislez M, Doubre H, Guisier F, Pichon E, Greillier L, Mastroianni B, Decroisette C, Schott R, Le Moulec S, Arrondeau J, Cortot AB, Gerinière L, Renault A, Daniel C, Falchero L, Chouaid C.
    Lung Cancer; 2019 Jan 01; 127():96-102. PubMed ID: 30642559
    [Abstract] [Full Text] [Related]

  • 14. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
    Sakai K, Takahama T, Shimokawa M, Azuma K, Takeda M, Kato T, Daga H, Okamoto I, Akamatsu H, Teraoka S, Ono A, Ohira T, Yokoyama T, Yamamoto N, Nakagawa K, Nishio K.
    Mol Oncol; 2021 Jan 01; 15(1):126-137. PubMed ID: 33131198
    [Abstract] [Full Text] [Related]

  • 15. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
    Zhao S, Li X, Zhao C, Jiang T, Jia Y, Shi J, He Y, Li J, Zhou F, Gao G, Li W, Chen X, Su C, Ren S, Zhou C.
    Lung Cancer; 2019 Feb 01; 128():33-39. PubMed ID: 30642450
    [Abstract] [Full Text] [Related]

  • 16. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation.
    Wang S, Yan B, Zhang Y, Xu J, Qiao R, Dong Y, Zhang B, Zhao Y, Zhang L, Qian J, Lu J, Zhao R, Han B.
    Int J Cancer; 2019 Jun 01; 144(11):2880-2886. PubMed ID: 30474188
    [Abstract] [Full Text] [Related]

  • 17. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
    Ahn MJ, Han JY, Kim DW, Cho BC, Kang JH, Kim SW, Yang JC, Mitsudomi T, Lee JS.
    Cancer Res Treat; 2020 Jan 01; 52(1):284-291. PubMed ID: 31345012
    [Abstract] [Full Text] [Related]

  • 18. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
    Provencio M, Terrasa J, Garrido P, Campelo RG, Aparisi F, Diz P, Aguiar D, García-Giron C, Hidalgo J, Aguado C, González JG, Esteban E, Gómez-Aldavarí L, Moran T, Juan O, Chara LE, Marti JL, Castro RL, Ortega AL, Moreno EM, Coves J, Sánchez Peña AM, Bosch-Barrera J, Gastaldo AS, Núñez NF, Del Barco E, Cobo M, Isla D, Majem M, Navarro F, Calvo V.
    BMC Cancer; 2021 Mar 06; 21(1):230. PubMed ID: 33676426
    [Abstract] [Full Text] [Related]

  • 19. Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer.
    Auliac JB, Saboundji K, Andre M, Madelaine J, Quere G, Masson P, Vergnenegre A, Lamy R, Raymond S, Chiappa AM, Hauss PA, Fournel P, Corre R, Chouaid C.
    Target Oncol; 2019 Jun 06; 14(3):307-314. PubMed ID: 31119481
    [Abstract] [Full Text] [Related]

  • 20. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
    Papadimitrakopoulou VA, Han JY, Ahn MJ, Ramalingam SS, Delmonte A, Hsia TC, Laskin J, Kim SW, He Y, Tsai CM, Hida T, Maemondo M, Kato T, Jenkins S, Patel S, Huang X, Laus G, Markovets A, Thress KS, Wu YL, Mok T.
    Cancer; 2020 Jan 15; 126(2):373-380. PubMed ID: 31769875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 96.